pharma news today glp-1 obesity GLP-1s and the Unintended Consequences of the $100 Billion Market As GLP-1 drugs for obesity

"Esses peptdeos, resumindo, funcionam como mensageiros biolgicos e enviam uma mensagem para a clula realizar determinada funo", explica Elisa Minami, cirurgi plstica e membro titular da Sociedade Brasileira de Cirurgia Plstica (SBCP)

Biosimilars Continue Their Momentum The biosimilar market grew substantially in 2025, and one of the biggest success stories was the introduction of Stelara biosimilars

Finally, RWS consistently reported better cardiovascular and renal outcomes of users of GLP-1RAs as compared to DPP-4 inhibitors users, and highlights the needs for further RWS comparing GLP-1RAs and SGLT-2i (and their combinations) on cardiovascular outcomes, that should eventually be confirmed by dedicated RCTs

The Wellness Pass Our Best Value for GLP-1 Clients Most clients on GLP-1 therapy stay on it for several months, and many find the Wellness Pass is the most cost-effective way to structure their program

So lets try taking you off the Ozempic, Wright said